Med Spa Technology: Leading Providers of HIPAA-Compliant Software Presented by Meevo

MedCity News's analysis-driven daily newsletter  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

Featured Story   Eli Lilly Strikes a Deal for CSL Drug What's the news? Eli Lilly has become an active dealmaker as it looks to build up its drug pipeline, and its latest one has the pharmaceutical company paying $100 million up front for rights to a drug from CSL Limited. This antibody, clazkizumab, previously failed in clinical testing for preventing rejection in organ transplant patients, but CSL has since advanced the drug to Phase 3 testing for preventing cardiovascular events in patients with end-stage kidney disease. CSL retains rights in this indication while Lilly gains rights to develop this drug for other conditions. The drug Clazkizumab is a monoclonal antibody designed to block IL-6, a signaling protein that, in excessive amounts, plays a role in chronic inflammation. IL-6-blocking drugs have already reached the market for certain inflammatory disorders, but there's renewed industry interest taking this approach to cardiovascular disease. Novo Nordisk and Novartis both have IL-6 antibodies from acquisitions. These companies have multiple clinical trials underway in a range of cardiovascular conditions. Why it Matters Cardiovascular disease has become a particular area of focus in Lilly's business deals in the past year. Last summer, Lilly acquired Verve Therapeutics, its partner in developing gene-editing medicines for cardiovascular indications. In January, Lilly reached a deal to buy Ventyx Therapeutics, a biotech that had reported positive mid-stage data for its small molecule inhibitor of NLRP3, a target associated with cardiovascular disease risk. Now clazakizumab gives Lilly the opportunity to bring another approach to cardiovascular conditions. Soundbite "Longer term, the durability of our cardiometabolic health product offerings and sustainability of our growth and prospects will depend on our ability to maintain or strengthen our competitive position as the therapeutic landscape evolves and to deliver further innovations that provide sufficient value to sustain our growth momentum," Lilly said in its annual report. —By Frank Vinluan Sponsored   Med Spa Technology: Leading Providers of HIPAA-Compliant Software Presented by Meevo Meevo is a leading HIPAA-compliant software for med spas, offering an all-in-one solution for beauty businesses. Created by Millennium Systems International (MSI), it provides tools that streamline daily operations and drive growth through data-driven insights, client management optimization and marketing features.  Learn More Top Stories   Solera Health Launches Behavioral Health Network What's the news? Solera Health, a digital health delivery company, unveiled its new behavioral health network on Tuesday with Calm Health and Lyra Health as partners. The behavioral health network The company's new behavioral health network expands beyond traditional mental health care, which focuses on conditions like anxiety and depression. Behavioral health includes mental health but also addresses habits and lifestyle factors — such as sleep, stress and daily routines — that influence overall well-being. To access behavioral health support, health plan members will come to Solera and answer questions about their needs and severity, as well as their preferences (such as if they prefer self-guided content or more intensive support). Based on their responses, Solera will send the member to Calm Health or Lyra Health, which deliver the actual behavioral health care and content to the member. Soundbite "One of our goals is to ultimately be able to provide the best behavioral health support that we can across any employer or health plan population. Be able to really meet the needs of any member coming in, no matter where on the spectrum they may fall," said Paige Baldwin, clinical program manager at Solera Health, in an interview. — By Marissa Plescia A Chat with Anthropic's Head of Biology and Life Sciences He was intentionally vague but … The interview with Eric Kauderer- Abrams happened in mid-January, and there were parts where he was intentionally vague – for instance, Anthropic wants to directly launch products instead of simply powering other people's AI aspirations, but he wouldn't say in what areas we would see those "first-party" products. … a vision is emerging Yes, it has Claude for paid consumer subscribers, but Claude and its agentic minions will be helping companies do their stuff better than before. For instance, Genmab will rely on agentic AI from Anthropic to support its clinical trial documentation for instance, among boosting other workflows through greater efficiency. It will also work with partners like Genmab and others to refine the foundational model on which partner companies are building their products. And where OpenAI is sticking to the consumer, helping them understand their medical records better, Anthropic wants to also be in the EHR. In fact, Kauderer- Abrams believes in the primacy of EHRs. Soundbite As we go, we're going to develop some new products too, and there will be change in behavior, but certainly your EHR interface is the main home base for patients, and it's critical that we bring our products there." Kauderer- Abrams said. — By Arundhati Parmar Accelerating Market Access Through Intelligent Decision-Making Failure to successfully launch The Gambler's Fallacy holds that, if you've called heads five times in a row and called wrong each time, the next toss is sure to be heads. Stay the course and your luck will change. Statisticians, of course, know this to be false. One of the main reasons 'the house always wins' is that gamblers often dupe themselves. Currently, more pharma launches miss expectations (58%) than meet or surpass them (42%), and yet pharma launch teams keep tossing the same coin in the hopes it will land on heads next time. Coin flips One of the key contributors to that 58% failure rate is that pharma companies have struggled to gain a complete understanding of complex, fast-moving markets, which is further intensified by the industry's move toward rare disease, oncology, and other specialty markets. Even when an organization has developed a good idea of what the market wants and needs, it's not always possible to act on that knowledge. Misalignment between medical and commercial teams interrupts the flow of insights and prevents teams from acting on market signals in a timely fashion. Strategic decisions that should be made confidently and informed by market signals become coin flips. Changing the odds AI has the ability to skew the odds in launch teams' favor. Commercial applications of artificial intelligence offer the greatest opportunity for value creation in the pharmaceutical industry, and are expected to generate 18-30 billion dollars of value annually. AI can reduce the launch failure rate by delivering accurate, actionable market signals in real time, enabling confident, informed decision-making. The pharmaceutical industry has been understandably slow to adopt AI tools for a variety of reasons. It's important to make a distinction between open-source LLMs such as ChatGPT, Copilot, and launch AI solutions that are specifically built and tailored for the pharmaceutical industry. Imagine the power to act faster, more decisively, and with greater confidence in your decisions than your competitors. Now that would be a win. — By MedCity Influencer Lance Hill Video   Video: OpenEvidence's Eye-Popping Valuation Explained Samir Batra, co-host of our Debunked YouTube show, explains more about OpenEvidence's remarkable user growth and valuation.

In Other News

Healthcare's AI Obsession Is Missing the Point on Nursing Shortages Healthcare leaders must resist using AI as a substitute for staffing. Instead, invest in workforce optimization technology that empowers nurses, creates flexible pathways, and addresses the systemic issues driving burnout.

Podcast   Debunked Episode 23: Companies Vie for Healthcare AI Dominance The conversation between MedCity News Editor-in-Chief Arundhati Parmar and Samir Batra, managing partner of Health Innovation Pitch, highlighted news from the J.P. Morgan Healthcare Conference, particularly how technology and biopharma companies are shaping AI in healthcare. View Now

MedCity News • PO Box 901 • New York, NY unsubscribe